DeAngelis Adrian F, Spinou Catherine, Tsui Alpha, Iseli Tim, Desai Jayesh, Wiesenfeld David, Chandu Arun
Head, Neck Oncology Tumour Stream, Department of Surgery, Royal Melbourne Hospital, Parkville, Victoria, Australia.
J Oral Maxillofac Surg. 2012 Mar;70(3):734-9. doi: 10.1016/j.joms.2011.03.020. Epub 2011 Jul 20.
To assess clinical behavior, response to treatment, and factors affecting survival in maxillofacial osteosarcoma treated at a tertiary referral center.
Ethics-approved retrospective review of clinical and pathological records was undertaken for 15 patients managed by the Royal Melbourne Hospital Head and Neck Oncology Tumor Stream.
Treatment was a combination of surgery and chemotherapy. Chemotherapy was given as adjuvant, neoadjuvant, or in combination. The overall 2-, 5-, and 15-year disease-free survival rates in this study were 92%, 74%, and 74%, respectively. Using Kaplan-Meier analysis with log rank tests, increasing T stage (P = .01) and positive margins (P = .003) were found to affect survival significantly. Neoadjuvant chemotherapy was not significantly associated with tumor necrosis or improved survival.
Tumor size and adequacy of local control were found to be the most important predictors of outcome.
评估在一家三级转诊中心接受治疗的颌面部骨肉瘤的临床行为、对治疗的反应以及影响生存的因素。
对由皇家墨尔本医院头颈肿瘤学肿瘤治疗组管理的15例患者进行了伦理批准的临床和病理记录回顾性研究。
治疗采用手术和化疗相结合的方式。化疗作为辅助、新辅助或联合治疗使用。本研究中总体2年、5年和15年无病生存率分别为92%、74%和74%。使用Kaplan-Meier分析和对数秩检验，发现T分期增加（P = .01）和切缘阳性（P = .003）对生存有显著影响。新辅助化疗与肿瘤坏死或生存率提高无显著相关性。
肿瘤大小和局部控制的充分性是结果的最重要预测因素。
